Serenoa repens, selenium and lycopene to manage lower urinary tract symptoms suggestive for benign prostatic hyperplasia

Andrea Russo, Paolo Capogrosso, Giovanni La Croce, Eugenio Ventimiglia, Luca Boeri, Alberto Briganti, Rocco Damiano, Francesco Montorsi, Andrea Salonia

Research output: Contribution to journalReview articlepeer-review


Introduction: Benign prostatic hyperplasia (BPH) is a disease affecting most of the elderly male. α1-blockers and 5-alpha reductase inhibitors are currently used to target lower urinary tract symptoms (LUTS). Moreover phytotherapeutic agents, including Serenoa Repens (SeR), have shown to have a role in ameliorating BPH/LUTS alone or in combination of other elements like Selenium (Se) and Lycopene (Ly). Areas covered: A literature review was performed using data from articles assessing the role of of SeR+Se+Ly in the management of LUTS secondary to BPH. Diverging evidence on SeR’s efficacy is available. On one hand several studies have shown SeR efficacy in treating BPH/LUTS. SeR is effective in reducing prostate size, urinary frequency, dysuria, nocturia and in improving maximum urine flow-rate. On the other hand two long-term trials reported that SeR did not improve prostate size or urinary flow. SeR+Se+Ly in combination with tamsulosin is more effective than single therapies in improving IPSS and increasing maximal urinary flow-rate in patients affected by LUTS/BPH. Expert opinion: Despite great amount of preclinical and clinical studies, the use of SeR in BPH/LUTS is not sustained by clear evidence for a therapeutic efficacy but current data hint higher efficacy of of SeR+Se+Ly compared to SeR alone.

Original languageEnglish
Pages (from-to)1661-1670
Number of pages10
JournalExpert Opinion on Drug Safety
Issue number12
Publication statusPublished - Dec 1 2016


  • BPH
  • LUTS
  • phytotherapy
  • prostate inflammation
  • Serenoa repens

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Serenoa repens, selenium and lycopene to manage lower urinary tract symptoms suggestive for benign prostatic hyperplasia'. Together they form a unique fingerprint.

Cite this